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Héctor Mayani1, Rogelio Hernandez-Pando6, Otoniel Martinez-Maza7, Sara Huerta-Yepez8, Benjamin Bonavida7†
and Mario I. Vega1,7*†
Abstract
Background: The p38 MAPK is constitutively activated in B-NHL cell lines and regulates chemoresistance.
Accordingly, we hypothesized that activated p38 MAPK may be associated with the in vivo unresponsiveness to
chemotherapy in B-NHL patients.
Methods: Tissue microarrays generated from eighty untreated patients with Diffused Large B Cell Lymphoma
(DLBCL) were examined by immunohistochemistry for the expression of p38 and phospho p38 (p-p38) MAPK. In
addition, both Bcl-2 and NF-κB expressions were determined. Kaplan Meier analysis was assessed.
Results: Tumor tissues expressed p38 MAPK (82 %) and p-p38 MAPK (30 %). Both p38 and p-p38 MAPK expressions
correlated with the high score performance status. A significant correlation was found between the expression p-
p38 and poor response to CHOP. The five year median follow-up FFS was 81 % for p38− and 34 % for p38+ and for
OS was 83 % for p38− and 47 % for p38+. The p-p38+ tissues expressed Bcl-2 and 90 % of p-p38− where Bcl-2−. The
coexpression of p-p38 and Bcl-2 correlated with pool EFS and OS. There was no correlation between the expression
of p-p38 and the expression of NF-κB.
Conclusion: The findings revealed, for the first time, that a subset of patients with DLBCL and whose tumors
expressed high p-p38 MAPK responded poorly to CHOP therapy and had poor EFS and OS. The expression of p38,
p-p38, Bcl2 and the ABC subtype are significant risk factors both p38 and p-p38 expressions remain independent
prognostic factors.
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Background
The term Diffuse Large B-Cell Lymphoma (DLBCL) is
applied to a heterogeneous group of clinically aggressive
disorders that collectively account for more than 30 % of
all new lymphoma diagnoses. DLBCL is the most com-
mon type of Non-Hodgkin Lymphoma (NHL) that
occurs in the western world, with different clinical,
immunophenotypic, and genetic abnormalities [1].
DLBCL is associated with an aggressive natural history
and a median survival of less than one year in untreated
patients [2]. The incidence of NHL increased dramatic-
ally from the 1970’s until 1990’s with an estimated of
over 60,000 new cases diagnosed in the United States
and around 30,000 in Mexico in 2011 [2]. Patients who
are diagnosed with DLBCL must undergo full stating
work-up which will determine the treatment schedule
and that may help to identify prognostic factors [3]. The
International Prognostic Index (IPI), proposed in 1993,
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outcomes [4]. However, the IPI was developed prior to
the rituximab (anti-CD20 mAb) era and has recently
been the subject of modifications for a better prediction
of the outcome [5].
Two biological distinct pathophysiologic entities of
DLBCL -as determined by gene expression profile-,
namely, the Germinal Center B-cell subtype (GCB) and
the Activated B-cell (ABC) subtype, and unclassified
subtypes, derived from different cells of origin [6]. Pa-
tients with GCB-DLBCL have a better survival span than
those with ABC-DLBCL [7]. Although the use of rituxi-
mab has improved the overall survival rates [8], however,
a survival advantage in patients with GCB-DLBCL
persists.
A number of prognostic markers have been suggested
for DLBCL, including p53, Myc, Bcl-2 and NF-κB [9].
However, different studies have shown divergent results
and the prognostic values for some of the markers are
still unclear. P38 MAPK (Mitogen-Activated Protein
Kinase) belongs to a class of serine/threonine kinases
[10] composed of four isoforms (α, β, γ and δ). P38 α
and p38 β MAPK are expressed in most tissues [11].
Phosphorylation of p38 activates a wide range of sub-
strates that include transcription factors, protein kinases,
cytosolic and nuclear proteins, all of which lead to di-
verse responses such as inflammation, cell differenti-
ation, cell-cycle arrest, apoptosis, senescence, cytokine
production and regulation of RNA splicing.
The role of p38 in cancer may depend on the cell type
and cancer stage. Some studies have reported that p38
MAPK increases tumor cell proliferation whereas in
others the activation of the p38 MAPK pathway results
in tumor suppression [12]. It remains to be determined
how these two opposing functions of p38 MAPK –medi-
ated signaling operate in vivo and how they may impact
cancer development [13]. Increased levels of activated
p38 MAPK (phospho (p)-p38 MAPK) have been corre-
lated with malignancy in follicular lymphoma and other
malignancies [14]. Our reported studies in B-NHL cell
lines have shown that treatment with rituximab inhibited
p-p38 MAPK expression, reduced Bcl-2 expression, and
chemosensitized such resistant cell lines to drug-induced
apoptosis [15]. Hence, the activation of the p38 MAPK
pathway has emerged as a major mechanism of rapid
cell proliferation and tumor cell resistance to cytotoxic
drugs [16]. The expression and activity of p38 MAPK
have been demonstrated to be key players in the cellular
response to several drugs used in cancer therapy [17].
Since the standard treatment to DLBCL includes ritux-
imab (R), several studies have been reported with con-
flicting observations concerning the prognosis of CHOP
versus R-CHOP-treated patients [18]. Interestingly, in
some countries of Latin-America, including Mexico,
some patients have no access to treatment with R-
CHOP and the usual treatment regimen for them is just
CHOP. Hence, we were interested to determine which
subset of patients with DLBCL may respond to treat-
ment with CHOP alone.
Based on our findings that the activation of p38
MAPK renders the tumor cells chemo-resistant [15], we
hypothesized that the expression and activation of p38
MAPK (p-p38 MAPK) may be inversely correlated with
the response to CHOP treatment in patients with
DLBCL. The present study was designed to test this hy-
pothesis and the followings were investigated: 1) the ex-
pression levels of p38 MAPK and p-p38 MAPK in a
cohort of tumor tissues derived from untreated DLBCL
patients who were subsequently treated with CHOP 2)
the determination whether the p38 MAPK and/or p-p38
MAPK expression level had a prognostic significance in
the context of treatment in response to CHOP and 3)
the assessment of the predictive value of p-p38 MAPK
expression as a biological marker for the unsuccessful
treatment with CHOP in patients with DLBCL that can-
not be treated with R-CHOP. The findings corroborated
the above hypothesis.
Methods
Patients and Tumor Specimens
We have retrospectively studied 80 tumor tissues from
DLBCL patients derived from the National Cancer Insti-
tute (Instituto Nacional de Cancerología INCan, SSA,
Mexico City), who subsequently received the CHOP
(Cytoxan, Doxorubicin, Vincristine and Prednisone)-
based chemotherapy regimen as first-line chemotherapy.
The patients studied fulfilled the following criteria: a)
Histopathological diagnosis of DLBCL according to the
WHO classification, b) the samples excluded patients
who were treated with CHOP plus rituximab and c) the
samples were from patients with no human immuno-
deficiency virus-infection. Cases with any confirmed fol-
licular architecture were not eligible for the study. The
disease stage was evaluated according to the Ann Arbor
staging system [19]. The scoring system for Performance
Status evaluation was according to the Eastern Corpora-
tive Oncology Group (ECOG) [20]. The clinical parame-
ters of the studied patients are summarized in Table 1.
The tumor response was evaluated according to the
WHO recommendations after 6 cycles of chemotherapy.
Fifty-two (65 %) patients showed completed remission
after CHOP therapy. This retrospective study was ap-
proved by the National Commission for Scientific Re-
search, the Ethics Board of the Mexican Institute for
Social Security (IMSS 2006-785-048) and it is in accord-
ance with the Declaration of Helsinki. A written in-
formed consent was obtained from each patient and all
lymphoma biopsies had been offered according to
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National Commission for Scientific Research of the
IMSS (CIS) guidelines.
The IPI was defined on the basis of five clinical vari-
ables (ages, performance status, stage, LDH level and
extranodal site involvement) and subdivided into IPI
groups as previously reported [21]: a low IPI score (0–2)
and a high IPI score (3–5).
Tumor tissues were fixed and embedded in paraffin
for routine histological and immunohistochemical stud-
ies at diagnosis. They were re-evaluated by two patholo-
gists (A A-S & R H-P) and the histological diagnosis was
established according to the current REAL/WHO cri-
teria. The pertinent clinical information of these patients
was obtained by reviewing the tumor registry records
and/or from the patient’s medical charts.
Immunohistochemistry
A tumor microarray (TMA) from the 80 DLBCL pa-
tients was constructed as previously described [22],
using 3 malignant tissue cores (0.5 mm diameter) per
tumor. The TMA sections were incubated overnight at
room temperature with ether anti-p38 or anti-p-p38
MAPK (Thr180/Tyr182; Santa Cruz) antibodies. Stand-
ard Immunohistochemical analysis was carried out for
Bcl-2 as previously reported [23]. The optimal cut-point
for Bcl-2 expression was determined by the method used
by Iqbal et al. [23]. For NF-κB analysis, a rabbit poly-
clonal anti-NF-κB p65 of human origin (NF-κB (C-20),
Santa Cruz Biotechnology) was used as previously re-
ported [24]. A standard detection system was then used
(Universal LSAB kit DAKO Corporation, Carpinteria,
CA, USA). The slides were then analyzed under light
microscopy (Olympus BX-40).
The GCB and ABC DLBCL subtypes were defined based
on the CD10, Bcl-6 and MUM-1 staining and according to
the algorithm developed by Hans et al. [22]. The GCB type
was defined as CD10+ or CD10−/Bcl-6+/MUM-1−,
whereas the ABC subtype was defined as CD10−/Bcl-6
−or CD10−/Bcl-6+/MUM-1+. The Additional file 1: Table
S1 summarizes the various antibodies used for analysis.
Semi-quantitative assessment of tissue antibody stain-
ing was conducted by an expert pathologist on lymph-
oma analysis (A A-S), who was blinded to the
pathological variables. The stained slides were verified
by a second expert to ensure consistency in scoring (R
H-P). The expression levels on the TMA’s were done
blindly. The TMA spot was a second blinded quantita-
tive assessment by the same pathologist. The target tis-
sue for scoring was done in the malignant cells by
considering the nuclear and cytoplasmic staining pattern
for p38 and p-p38. Data are presented as positively
stained target cells per 100 cells (range 0–100 % posi-
tive), per tissue region in the TMA (4 regions in each
TMA spot). We have calculated the percentage of posi-
tive staining by using the thresholds of ≤ 30 % of stained
cells as negative. Stained cells that are ≥ 30 % were con-
sidered as positive. All of the results are expressed ac-
cording to these calculations. To establish the positivity
and the threshold (30 %), we categorized by analysis as
defined by the ROC curves and by the Younden index in
order to separate the percentages depending on the re-
sponse to treatment. Overall differences were compared
by the log-rank test. The tumor response was evaluated
according to the WHO recommendations after each of
the 6 cycles of chemotherapy.
Statistical analyses
Survival curves were estimated by the Kaplan-Meier
method with differences compared by the log-rank test
[25], whereby the event-free survival (EFS) and the over-
all survival (OS) were considered the main outcomes of
the study. The EFS was calculated from the date of diag-
nosis to the date of documented disease progression, re-
lapse or death from any cause. The OS was calculated
Table 1 Clinical parameters of patients with DLBCL
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from the date of diagnosis until death from any cause or
the last follow-up. Comparisons of the clinical character-
istics between the p38 MAPK and p-p38 MAPK-positive
and negative groups were determined by the Fisher’s
exact test and by the Student’s t-test. Cox multivariate
analysis was carried out to estimate the prognostic im-
pact of the biomarkers and IPI risk factors in both the
EFS and the OS. The data were analyzed using the
Graph Pad Prism-5 software for windows (La Jolla, CA).
Results
Patient characteristics
In this study, 80 patients with DCBCL that were treated
with CHOP at the National Institute of Cancer (INCan,
SSA, Mexico) between 2000 and 2005 were analyzed.
The clinical characteristics of those patients are listed in
Table 1. Twenty three (28 %) patients were included in
the high IPI group. Twenty (25 %) patients were in-
cluded in the high (2–4) Performance Status. Bcl-2 was
expressed in 30 (37 %) patients. None of the Bcl-2+ pa-
tients had history of other lymphoproliferative disorders.
Fifty eight patients (72 %) were categorized into the GC
subtype and 22 (28 %) into the ABC subtype. Twenty six
patients (32 %) expressed p65 and p50 NF-κB and 13 pa-
tients (16 %) expressed p50 NF-κB. (Additional file 2:
Figure S1). Fifty two patients showed a disappearance of
all evidence of disease and negative PET and were classi-
fied as responders (R). The remaining 28 patients, with
any new lesion or an increase by ≥ 50 % of previously in-
volved sites, were classified as non-responders (NR).
Clinical and biological features in relation to p38 MAPK
and p-p38 MAPK expressions
The expressions or lack of expressions of p38 MAPK
and p-p38 MAPK in representative samples are shown
in Fig. 1. Figure 1a shows the detection of p38 expres-
sion in tumor cells. Figure 1b shows the detection of p-
p38 expression in tumor cells and Fig. 1c shows the
absence of detection of p38. The IgG isotype was used
as a specificity control and is shown on the right panel.
The analysis of the expression pattern in all of the tumor
specimens showed that 66/80 (82 %) of tumor tissues
were p38+ and 24/80 (30 %) were p-p38+ (Fig. 1d). The
expression patters of p38+, p38−, p-p38+, and p-p38 −
were analyzed as a function of the patients clinical char-
acteristics. No significant differences were observed
among the above four subgroups with regards to the dis-
tribution of patients characteristics including the IPI
score (67 % vs 50 % High IPI 3-5/p-p38, p > 0.5; 56 % vs
57 % High IPI 3-5/p38, p > 0.5), stage of disease (67 % vs
64 % with stage III-IV disease/p-p38, p > 0.4; 67 % vs
57 % with stage III-IV disease/p38, p > 0.4), lactate de-
hydrogenase (LDH; 50 % vs 67 % with elevated LDH/p-
p38, p > 0.3; 61 % vs 71 % with elevated LDH/p38, p >
0.3). However, there were more p-p38 expression in pa-
tients with poor PS (p < 0.01) (Table 2). These results
suggested that high p-p38 expression correlated with a
Fig. 1 Expression of p38 MAPK and p-p38 MAPK in patients with DLBCL Tissue microarray-based immunohistochemical analyses of p38 MAPK
and p-p38 MAPK in representative tumor biopsies from DLBCL patients. DLBCL array cores showing over-expression of p38 MAPK (a), high
expression of p-p38 MAPK (b) and another DLBCL tissue array core shows no or low expression of p38 MAPK (c). 40X objective on an Olympus
BX 51 microscope (Olympus America, Center Valley, PA, USA), (Left) and 100X aperture view of the same tissue (Right). Of the 80 DLBCL biopsies
analyzed, 82 % were positive for p38 and only 30 % were positive for p-p38 MAPK (d). The percentages were calculated based on the threshold
used for ≤ 30 % expressed cells considered negative and≥ 30 % stained cells were considered positive as descried in methods
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poor performance status and can have a greater impact
on an individual’s prognosis. The ABC subtype was also
influenced by higher p-p38+ (92 %) and p38+ (34 %) (p <
0.01). In the GC subtype, only 2/24 (8 %) were p-p38+
and 44/66 (66 %) were p38+ (p < 0.05).
For NF-κB expression, there were no significant differ-
ences observed among the four subgroups according to p-
p38 or p-38 expression. Seventy-seven percent of patients
with p-p38− were also negative for NF-κB and 70 % of pa-
tients with p38+ were negative for NF-κB. There was no
correlation between these groups (Table 2). The predictive
role of p-p38 expression was evaluated by using ROC ana-
lysis, which was performed by estimating the percentage
of p-p38 expression according to treatment response and
all the patients with over 30 % were established as positive
for p-p38 expression (data no shown).
The above findings demonstrated that both the PS and
the ABC subtype of tumor tissues exhibited high p-p38
expression.
Relationship between the p38 and p-p38 expressions in
tumor tissues and the response of patients CHOP therapy
Fifty two (65 %) of the 80 patients examined in this
study were classified as responders (R) and 28 (35 %)
were classified as non-responders (NR) to CHOP treat-
ment. A comparison between the R and NR for the ex-
pression of p38 demonstrated that the NR patients
showed higher expression of p38 than found in the R pa-
tients (Fig. 2a) (p < 0.05). Noteworthy, the expression of
p-p38 was significantly higher in the NR patients than in
the R subgroup of patients (Fig. 2b) (p < 0.005). Figure 2c
summarizes the findings for p-p38 expression and dem-
onstrate that the majority of tumor tissues from the NR
showed higher expression of p-p38, suggesting that p-
p38 expression may be involved in the resistance to
CHOP treatment. The correlation between high p-p38
expression and poor response to CHOP treatment is sig-
nificant (Fig. 2c).
Clinical outcomes according to the expression of p38 and
p-p38 MAPK
We examined the clinical outcomes of patients based on
p38 expression by the Kaplan-Meier analysis. After a
median follow-up of 60 months, the EFS was 81 % for
the p38− tumor tissues and 34 % for the p38+ tumor tis-
sues (p = 0.004) (Fig. 3a). Further, the 5-year OS was
83 % for the p38− tumor tissues vs 47 % for the p38+
tumor tissues (p = 0.001) (Fig. 3b). These findings
Table 2 Patients characteristics in relation to p38 MAPK and p-p38 MAPK expressions
Features p-p38+ (n = 24), n (%) p-p38- (n = 56), n (%) p38+ (n = 66), n (%) p38- (n = 14), n (%) p
Sex:
Male 16 (64) 29 (52) 40 (61) 6 (42) 1.0
Female 8 (36) 27 (48) 26 (39) 8 (58)
Age: Media, range 55, 30–65 60, 25–72 46, 20–68 53,15–75 0.74
Stage:
1–2 8 (33) 20 (36) 22 (33) 6 (43) 0.26
3–4 16 (67) 36 (64) 44 (67) 8 (57) 0.44
LDH:
Normal 15 (50) 27 (33) 30 (39) 12 (29) 0.38
High 9 (50) 29 (67) 36 (61) 2 (71) 0.33
IPI
0–2 19 (33) 38 (50) 47 (44) 10 (43) 0.31
3–5 5 (67) 18 (50) 19 (56) 4 (57) 0.51
PS > 1 *8 (33) *5 (9) *17 (26) *1 (7) * < 0.01
Bcl-2
Positive *24 (100) *6 (10) 29 (45) 7 (50) *0.003
Negative *0 (0) *50 (90) 37 (55) 7(50) *0.007
GC type ‘2 (8) *56 (100) *44 (66) *14 (100) * < 0.05
ABC *22 (92) *0 (0) *22 (34) *0 (0) * < 0.01
NF-kB
Positive 13 (54) 26 (46) 26 (40) 6 (42) 0.82
Negative 11 (46) 30 (54) 40 (60) 8 (57) 0.96
IPI International Prognostic Index, LDH Lactate Dehydrogenase, PS Performance status, GC germinal Center, ABC Activated B-Cell
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demonstrated the impact of p38+ expression in tumor
tissues on both the EFS and the OS.
In addition, we examined the clinical outcomes of pa-
tients based on p-p38 expression by the Kaplan-Meier
analysis. The 6-year EFS was 83 % for p-p38− tumor tis-
sues and 33 % for p-p38+ tumor tissues (p = 0.001)
(Fig. 3c). The 5-year OS was 74 % for the p-p38− tumor
tissues vs 58 % for the p-p38+ tumor tissues (p < 0.001)
(Fig. 3d).
Overall, the above findings demonstrated the impact
of not only for p38 but also for p-p38 expression in
tumor tissues on both the EFS and the OS.
Relationship between the expression of p38 or p-p38 and
the expression of Bcl-2 on clinical outcomes
Bcl-2 expression was also determined in this study. Con-
sistent with the literature, 37 % of the 80 cases that were
analyzed for Bcl-2 were scored as positive [26] (Table 2).
There were no significant differences in the percentages
of patients with elevated LDH (45 % vs 52 %), High IPI
(56 % vs 68 %), median age (p = 0.6), stage III-IV (p =
0.5), when compared according to Bcl-2 expression (data
no shown). Interestingly, the performance status >1
showed significant differences between Bcl-2 positive
and negative subgroups (p = 0.05), similar to the p38 and
p-p38 expressions (data no sown).
Several studies have reported the prognostic signifi-
cance of Bcl-2 in DLBCL [25]. Accordingly, we have de-
termined the correlation between p-p38 and Blc-2
expressions, based on our previous in vitro results,
whereby the p38 MAPK expression correlated with Bcl-
2 expression and the inhibition of either p38 or Bcl-2-
induced chemosensitization to drugs [15].
We analyzed the relationship between the co-
expression of the p38 or p-p38 and Bcl-2 expression in
tumor tissues. All of the tissues that were p-p38+ were
also Bcl-2+. Interestingly, 90 % of p-p38− tissues were
also Bcl-2−. With respect to p38 expression, 44 % of the
p38+ tumor tissues were Bcl-2+ (p < 0.005). Noteworthy,
tumor tissues that were p38− were also Bcl-2− (p = 0.01)
(Table 2).
The clinical outcome of tumor tissues co-expressing
p38/p-p38 and Bcl-2 were analyzed by Kaplan Meier
(Fig. 4). The five-year EFS scores were 28 %, 45 %,
100 %, and 86 % for the p38+/Bcl-2+, p38+/Bcl2−, p38
−/Bcl-2+, p38−/Bcl-2− subgroups, respectively (Fig. 4a).
In comparison with the other subgroups, there was a
lower risk of EFS for the p38−/Bcl-2+ and p38−/Bcl-2−
tissues (p = 0.004). When the p-p38 expression positivity
was considered, the five-year EFS scores were 30.6 %,
64.5 %, and 81 % for the p-p38+/Bcl-2+, p-p38−/Bcl-2+,
p-p38−/Bcl-2−, respectively, and the p-p38+/Bcl-2− sub-
group was not detected (Fig. 4c). By comparison, we ob-
served a lower risk of EFS for the p-p38−/Bcl-2− and p-
p38−/Bcl-2+ subgroups (p = 0.001). The five-year OS
rates for p38 expression were 30 %, 46.7 %, 90.9 %, and
89.9 % for the p38+/Bcl-2+, p38+/Bcl-2−, p38−/Bcl-2+,
p38−/Bcl-2− subgroups, respectively (Fig. 4b). Patients’
tumors that were p38−/Bcl-2− and p38−/Bcl-2+ had
higher OS than those in the other two subgroups (p =
Fig. 2 p38 MAPK and p-p38 MAPK expressions in non-responders DLBCL patients. a p38 MAPK expression according to the clinical response. P38
MAPK expression was assessed by IHC in 80 biopsies. The % expression was calculated from the TMA p38 MAPK staining. Black lines represent the
medians, whiskers marking the lower and upper adjacent values. b p-p38 MAPK expression in responder (R) and non-responder (NR) patients. The
% of tumor samples expressing p-p38 was determined from the TMA staining of p-p38 MAPK. c There is a significant expression of p-p38 MAPK
in the NR. The % of p-p38 MAPK expression was determined in TMA and the % threshold (30) was defined by the ROC curves and by the Younden
index to separate the % depending on the response to treatment
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0.001). The five-year OS rates were 30.6 %, 64.5 %, and
81 % for the p-p38+/Bcl-2+, p-p38−/Bcl-2+, p-p38−/Bcl-2−
subgroups, respectively, and p-p38+/Bcl-2− was not de-
tected (Fig. 4d). Tumor tissues from patients showing p-
p38−/Bcl-2− and p-p38−/Bcl-2+ had higher OS than the
other two subgroups (p = 0.001). According to observa-
tions reported in other studies [23], the differences in
response rates were noted according to Bcl-2 expression
(p = 0.005), EFS (p = 0.05) or OS (p = 0.005), similar to
those observed with p-p38 expression.
In addition, we compared the survival curves for sub-
groups based on their co-expression of p38, p-p38 and the
GC/ABC subtypes available in the cohort of this study.
The 5-year EFS scores for the p38+/GC, p-p38+/ABC, and
p-p38−/GC subgroups, were 78.3 %, 88.6 %, and 0 %, re-
spectively (Fig. 4e). Patients in the subgroups p38+/GC
and p-p38−/ GC had a lower risk of recurrence than the
other two subgroups (p < 0.001). For the OS for 5 years,
the scores were 69 %, 95.9 %, and 9.2 %, respectively
(Fig. 4f). The patients in the groups p38+/GC and p-p38
−/GC showed a higher OS than the other subgroups (p <
0.001). Similar to the expression of Bcl-2, the ABC sub-
type correlated with p-p38 expression and had poor EFS
and OS. Comparing GC and ABC subgroups, there were
marginal differences in the percentages of patients with el-
evated LDH (55 % vs 62 %), High IPI (64 % vs 70 %), stage
III-IV (44 % vs 53 %), with the exception of a marginal
higher percentage of performance status >1 (43 % vs
74 %). Similar to a previously reported study [27] the dif-
ferences in response rates were observed (p = 0.005), EFS
(p = 0.001) or OS (p = 0.005) and were noted according to
the GC vs ABC phenotypes (data not shown).
The above findings demonstrated that the co-
expressions of Bcl-2 and p-p38 are an indicator of poor
EFS and OS. Further, the co-expression of Bcl-2 with p-
p38 correlated with low EFS scores and poor OS for the
patient’s tumor with the ABC subtype.
Prognostic impact of p-p38 expression
We examined the prognostic impact of tumor tissues ex-
pressing p-p38 as a biomarker with respect to CHOP
therapy. Cox multivariate analyses were performed for
the p-p38 positivity in the R and NR subgroups and
adjusted for the Bcl-2 and the immunophenotype
categorization. As shown in Table 3, the expression of p-
p38 had a significant prognostic value for both EFS and
Fig. 3 Impact of p38 and p-p38 expressions on the prognosis of DLBCL patients. a Event-free survival (EFS) curves for DLBCL patients treated with
CHOP according to p38 MAPK expression. The curves correspond to positive (n = 66) versus negative (n = 14) p38 MAPK expression b. Overall sur-
vival (OS) curves for DLBCL patients treated with CHOP according to p38 MAPK expression. c EFS curves according to the p-p38+ MAPK
expression (n = 24) versus p-p38-MAPK (n = 56) d. Overall survival (OS) curve for DLBCL patients treated with CHOP according to positive p-p38
MAPK expression (n = 24) versus p-p38− MAPK expression (n = 56)
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OS with an association to the ABC subtype and Bcl-2
expression. Multivariate analyses showed p-p38 expres-
sion (p < 0.05, HR = 2.54, 95 % CI 1.01–6.4), Bcl-2 ex-
pression (p < 0.05, HR = 2.26, 95 % CI 1.04–7.21) and the
ABC subtype (p < 0.05, HR = 1.69, 95 % CI 1.07–3.63) to
be independent factors associated with EFS (Table 3).
Multivarite Cox analyses also indicated that p-p38 ex-
pression (p < 0.05, HR = 2.93, 95 % CI 1.13–7.5) and Bcl-
2 expression (p < 0.05, HR = 3.33, 95 % confidence inter-
val 1.28–6.63) and the ABC subtype (p < 0.05, HR = 2.45,
95 % CI 1.68–4.56) to be independent factors associated
with OS (Table 3). When the relative risk was estimated
with respect to the p-p38 expression after adjusting for
IPI and Bcl-2 expressions, the p-p38 status in combin-
ation with high IPI and Bcl-2 expression were
Table 3 Multivariate analysis of risk factors of EFS and OS of
DLBCL patients treated with CHOP
Relative risk 95 % Cl P
EFS
P-p38+ 2.54 1.01–6.4 <0.05
Bcl-2+ 2.26 1.04–7.21 <0.05
ABC 1.69 1.07–3.63 <0.05
OS
P-p38+ 2.93 1.13–7.5 <0.05
Bcl-2+ 3.33 1.28–6.63 <0.05
ABC 2.45 1.68–4.56 <0.05
Cl Confidence intervals, EFS event-free survival, OS overall survival
Fig. 4 Clinical outcomes according to p-p38 MAPK, Bcl-2 expression and the DLBCL phenotype. a Event-free survival (EFS) curves for DLBCL
patients treated with CHOP according to p38 MAPK and Bcl-2 expressions. b. Overall survival (OS) curves for DLBCL patients treated with CHOP
according to p38 MAPK and Bcl-2 expressions. The p38 MAPK negative and Bcl-2 negative subgroups had more favorable PFS and OS than did
the other two groups. c EFS curves according to the p-p38 MAPK and Bcl-2 expressions. d OS curves for DLBCL patients treated with CHOP
according to p-p38 MAPK and Bcl-2 expressions. The p-p38 MAPK negative and Bcl-2 negative or positive subgroups had more favorable PFS and
OS than did the other group. e EFS curves according to the p38 MAPK expression, p-p38 MAPK expression and the GC or ABC subtype. f Overall
survival (OS) curve for DLBCL patients treated with CHOP according to p38 MAPK expression, p-p38 MAPK expression and the GC or ABC subtype.
The p38 MAPK or p-p38 MAPK negative and GC subgroups had more favorable PFS and OS than did the other two groups
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determinants of EFS (p < 0.05) and death (p < 0.05),
(Additional file 3: Table S2). These data identified Bcl-2
expression, the ABC subtype and p-p38 expression as
significant risk factors for inferior EFS and OS in
DLBCL lymphoma. Noteworthy, the expressions of both
p38 p-p38 remained as prognostic factors even upon ad-
justments for both the Bcl-2 expression and the ABC
categorization.
Discussion
The present study demonstrates a significant correlation
between the expression of p38 and p-p38 MAPK and
the development of resistance to CHOP treatment in pa-
tients with DLBCL. The patient population studied in
this report was primarily treated with CHOP only and
rituximab was not an option for these patients. The p-
p38 MAPK expression is increased in clinical tissue
samples from untreated patients who were found subse-
quently to be resistant to CHOP chemotherapy. Kaplan
Meier showed that patients’ tumor tissues expressing
p38 or p-p38 experienced reduced EFS and shorter OS
compared to patients’ tumor tissues with no expression
of p38 or p-p38 and experienced longer EFS and OS. In
addition, there was a significant correlation between the
expression of Bcl-2 and p-p38, however, the EFS and OS
correlated primarily with only the expression of p38 or
p-p38 irrespective of Bcl-2. In addition, we show here
that the expression of either p38 or p-p38 MAPK is an
independent prognostic biomarker from the expression
of Bcl-2.
The role of p38 MAPK in cancer depends on the cell
type and cancer stage. Some studies have reported that
it plays a role as an oncogene whereas in other studies
the expression of p38 MAPK is described as a tumor
suppressor. For example, p38α expression is down regu-
lated in lung tumors, suggesting that p38 loss could be
related to tumor formation [12]. Consistent with these
findings, the expression of MKK4, a p38 activator, is re-
duced in advanced tumors [28]. Conversely, increased
levels of p38α have been correlated with malignancy in
follicular lymphoma, lung, thyroid, breast carcinoma, gli-
oma, and head and neck squamous cell carcinoma [14].
In colorectal cancer, p38α is required for cell prolifera-
tion and survival and its inhibition leads to cell-cycle ar-
rest and autophagic cell death [16]. In addition, higher
level of p-p38 in colon tumor samples from patients cor-
related with refractoriness to irinotecan-based therapy
[29]. p38 activation contributes to tamoxifen resistance
in ER-positive breast tumors [30]. More recently, it has
been shown that p38 inhibition enhances the sensitivity
to arsenic trioxide and bortezomib in multiple myeloma
[31]. Malignant B cells from SLL/CLL patients had
higher basal levels of p-p38 compared to healthy donor
B cells [32].
Here we show an impact of p38 and p-p38 expressions
on the prognosis of DLBCL that has not been previously
reported. The findings showed a worse EFS and OS in
patients tumors with p38+ and p-p38+ compared with
patients tumors with p38− and p-p38−. In our cohort,
the expression of single p38+ or p-p 38+ had an impact
on survival, and its association with poor PFS. These find-
ings suggested that p38 and p-p38 expressions had an un-
favorable prognostic effect in patients with DLBCL.
Previous related studies showed increased expression
of the p38 MAPK transcript and protein in a subset of
DLBCL arising from follicular lymphomas [33]. Similar
observations were obtained by Ogasawara et al. [34] who
found that freshly prepared cells from B cell lymphomas
showed constitutive in vitro activity of p38 MAPK and
ERK but not Ras, Akt kinase, and JNK kinase. These obser-
vations suggest that the constitutive activation of the p38
MAPK pathway may be implicated in lymphomagenesis.
The high p-p38 MAPK expression in reported studies
and in the present study may be reflective of the pres-
ence of cytokines or growth factors that activate the p38
MAPK pathway in these tumors. Reported studies have
indicated that the constitutive activation of the p38
MAPK pathway may be regulated by IL-4 with stimula-
tory effects on gene expression, protein levels, and in
vitro kinase activity. These data suggested a possible
role for IL-4-mediated activation of the p38 MAPK
signaling pathway in the pathogenesis of B cell lymph-
omas [35].
We have found that 100 % of p-p38 MAPK positive
tumors were also positive for Bcl-2 expression (Table 2).
Bcl-2 is an anti-apoptotic protein involved in the regula-
tion of programmed cell death [36]. Bcl-2 overexpression
was associated with poorer survival in the pre-rituximab
era [37]. In contrast, Bcl-2 expression was not identified
as a prognostic factor by Hans et al. [22]. However, sev-
eral other studies have reported the prognostic value of
Bcl-2 expression in patients with DLBCL [37, 38]. This
association of Bcl-2 expression with survival in DLBCL
patients treated with CHOP or CHOP-like regimens had
conflicting results [39]. Conflicts about the prognostic
significance of Bcl-2 expression have been attributed to
the heterogeneity of DLBCL. Recent studies reported
that the controversial results can be explained in the
context of the cell origin of DLBCL. Bcl-2 overexpres-
sion in ABC-DLBCL patients treated with CHOP regi-
mens have poor prognosis [39], probably due to the
tumor cells’ ability to resist apoptosis induced by chemo-
therapy. The addition of rituximab to CHOP regimens
for DLBCL has led to a significant increase in patient’s
survival and is now considered a standard regimen for
DLBCL. Controversial results have also been reported
for the association of Bcl-2 expression in R-CHOP-
treated cohorts; in general, Bcl-2 expression influences
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the relative risk in OS in Bcl-6+ DLBCL but not in the
Bcl-6− cases [37]. The inclusion of the expression and
activation of p38 MAPK as diagnostic markers can limit
the heterogeneity of this subgroup of patients. It has
been suggested that the expression and activity of p38
MAPK may be considered as prognostic factors and can
lead for the choice of appropriate treatment regimens
[40]. According to our previous in vitro results [15] and
clinically extended studies [41, 42], it was suggested that
patient’s tumors with p38 MAPK activation and which
are Bcl-2 positive reflected a chemoresistant phenotype.
Such patients may respond to chemotherapy used in
combination with rituximab since our in vivo and in
vitro studies revealed that the rituximab treatment in-
hibits the p38 MAPK/Bcl-2 pathway [15] and sensitizes
the resistant tumor cells to drug-induced apoptosis.
However, patients were not responding to CHOP and
don’t have the treatment option with rituximab, we sug-
gest that inhibitors of the p38 MAPK may reverse
resistance.
Due to our present findings that all tumors that are
positive for p-p38 expression are also positive for Bcl-2,
the relationship between p38 activation and Bcl-2 ex-
pression may be mediated by transcriptional and post
transcriptional mechanisms, which may affect the anti-
apoptotic Bcl-2 family proteins [43]. We and other have
reported that p38 MAPK can mediate the transcriptional
expression of IL-10 via the Sp1 transcription factor
and upon IL-10 interaction with its cognate receptors
it induces the activation of Stat-3 and Bcl-2 expression
[15, 44]. It is known that the interaction between Bcl-2
and p38 MAPK can directly regulate either its activity
or indirectly via the transcriptional regulation through
NF-κB activation [45].
NF-κB is centrally involved in lymphomagenesis and
tumor progression in various types of lymphoma. Over-
expression of NF-κB in tumor tissues has previously
been observed in NHL [46]. Recent studies have con-
firmed that NF-κB expression was predominantly seen
in ABC-DLBCL [47]. Our previous findings have impli-
cated the NF-κB pathway in the p38 MAPK/Bcl-2 circuit
of chemoresistance [15]. However, in this study we did
not find a correlation between the clinical features for
p38 MAPK expression and NF-κB expression. We have
further shown that 54 % of p-p38 MAPK+ are positive
for NF-κB, while the remaining 46 % of those patients
were negative for NF-κB (Table 2). Previous studies have
shown that ABC-DLBCL tumors exhibit higher expres-
sion levels of NF-κB target genes than those found in
the GBC subtype [47]. The constitutive NF-κB signaling
pathway confers a chemoresistant phenotype in NHL
cell lines [46]. Treatment with either specific chemical
inhibitors or with rituximab reverses chemoresistance or
results in the selective cytotoxicity in NHL or ABC-
DLBCL cell lines, respectively [48]. It has been shown
that the p38 MAPK pathway is involved in the activation
of NF-κB through the phosphorylation of MSK 1/2 dir-
ectly or mediated through H3 phosphorylation [49].
However, the present findings did not establish a roll of
NFκB in the response of CHOP. We suggest that the ac-
tivation of p38 MAPK may be the result of other regula-
tory mechanisms.
When we analyzed several clinical parameters for the
p38 and p-p38 MAPK expressions, we have found no
significant differences among the four subgroups with
regards to gender, age disease stage, LDH levels, and the
IPI score. In contrast, poor performance status was the
only dependent risk factor for p-p38 MAPK expression in
our DLBCL cohort. Several clinical parameters such as el-
evated serum, LDH levels and extranodal or bone marrow
involvement have been established as risk factors for re-
lapse in DLBCL [50]. The performance status is measured
by a performance score that takes into account several fac-
tors. We cannot establish if poor PS and p-p38 MAPK ex-
pression have a correlation with OS in our cohort.
However, we have analyzed the correlation between the
expressions of p38, p-p38 MAPK and the DLBCL subtype.
Interesting, our results showed that the ABC subtype cor-
relates with p-p38 expression. Multivariate analysis con-
firmed that the ABC subtype with p-p38 expression is
associated with unfavorable EFS and OS.
Conclusions
Altogether, the present findings show that activated p-p38
was expressed in 30 % of DLBCL and such an expression
was associated with the ABC phenotype and poor survival.
In addition, p38 expression was associated with no re-
sponse to the CHOP regimen. Considering the potential
prognostic and therapeutic roles of p38 and p-p38 MAPK,
we suggest their inclusion as additional biomarkers for
diagnosis in untreated tumor specimens. The positive ex-
pression predicts failure to CHOP treatment alone in a
subset of patients and it is recommended that a combin-
ation therapy with R-CHOP be considered for this sub-
set of patients or the use of inhibitors of p38 MAPK.
In addition, from the potential prognostic utility of p38
MAPK expression, the findings reported herein may
help future investigations to determine the clinical use-
fulness of specific chemical inhibitors of the p38
MAPK pathway in the treatment of DLBCL in combin-
ation with conventional CHOP regimens.
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expression of p65 (B). 40X objective on an Olympus BX 51 microscope
(Olympus America, Center Valley, PA, USA), (Left) and 100X aperture view
of the same tissue (Right). Of the 80 DLBCL biopsies analyzed, 16 % were
positive for p50 and 32 % were positive for p65 (C). (JPEG 75 kb)
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